Alphabet Inc. Owned DeepMind’s First Commercial Product Will Diagnose the Eyes
DeepMind is nearly ready to launch its first commercial product and it wants to start with helping the medical fraternity in treating complicated eye ailments. The foray makes DeepMind hope that the product will be its parent company Alphabet Inc’s maiden medical device.
DeepMind has already demonstrated a use case to prove the effectiveness of their product. A patient was performed upon a retinal scan through DeepMind’s capabilities, the results of which provided a diagnosis and the emergency level in just 30 seconds. The ability to diagnose this fast ensures that doctors get ample free time for other important tasks and patients who would receive urgent medical care for their eye(s).
DeepMind has already inculcated a range of eye-related disease diagnoses in its product, some of which are –
- Macular degeneration
- Diabetic retinopathy
DeepMind collaborated with London’s Moorfields Eye Hospital to ensure that the system is at par with accuracy levels of seasoned eye specialists. DeepMind Health, which is the maker of the product, was under fire recently from the British Government that claimed the company inappropriately accessed medical data of 1.6 million patients while it was developing its Streams App. Also, DeepMind is facing some difficulty trying to retain its able workforce.
DeepMind will have to be a little cautious when navigating through unchartered lands. The initiative is a prerequisite for DeepMind’s reputation and for the general public to have faith in their products. The research was first published with positive reviews in a science journal in August 2018. DeepMind has been highly appreciated for the depth and innovation of their products – but for Alphabet to continue backing it up, DeepMind will have to be proactive in building transparent and safe products.